Myelofibrosis (MF) Market Report 2026

The myelofibrosis (mf) market size has grown steadily in recent years. It will grow from $1.55 billion in 2025 to $1.6 billion in 2026 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to limited treatment options available, high prevalence of anemia in mf patients, rise in autoimmune-related conditions, increased diagnostic challenges, reliance on corticosteroid-based management.

The myelofibrosis (mf) market size is expected to see steady growth in the next few years. It will grow to $1.8 billion in 2030 at a compound annual growth rate (CAGR) of 3%. The growth in the forecast period can be attributed to advancements in jak inhibitor development, growing adoption of precision medicine, increased investment in hematology r&d, expanding stem-cell therapy advancements, rising availability of targeted oral therapies. Major trends in the forecast period include increasing adoption of jak inhibitor-based therapies, growing focus on combination treatment approaches, rising emphasis on early diagnosis and screening programs, expanding research in stem-cell transplantation and regenerative care, increased use of supportive care to manage symptom burden.

The growing demand for targeted therapies is expected to propel the growth of the myelofibrosis (MF) market going forward. Targeted therapies represent a medical approach that customizes treatment and healthcare decisions based on individual genetic, environmental, and lifestyle factors. The rising preference for targeted therapies is driven by advances in genomics, biotechnology, and data analytics, which enable more precise, effective, and personalized treatment options. In myelofibrosis, the identification of key molecular pathways such as JAK-STAT signaling has enabled the development of precision treatments, including JAK inhibitors such as ruxolitinib, fedratinib, and pacritinib, which help manage symptoms and slow disease progression. For instance, in May 2024, according to the American Cancer Society, a US-based non-profit organization, approximately 81,610 new kidney cancer cases were projected in the United States for 2024, along with an estimated 14,390 related deaths. Therefore, the growing demand for targeted therapies is driving the growth of the myelofibrosis (MF) market.

Major companies operating in the myelofibrosis (MF) market are concentrating on expanding targeted therapy options, including JAK1/JAK2 and ACVR1 inhibitors, to improve treatment effectiveness, address disease progression, and enhance patient outcomes. JAK1/JAK2 inhibitors act on the Janus kinase pathway to reduce inflammation and abnormal blood cell production associated with myelofibrosis, while ACVR1 inhibitors target activin receptor-like kinase 2 (ALK2) to help regulate bone marrow fibrosis and disease advancement. For instance, in September 2023, GSK plc, a UK-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for Ojjaara (momelotinib) for the treatment of patients with intermediate- or high-risk myelofibrosis. Its dual mechanism of action targeting both JAK1/JAK2 and ACVR1 supports inflammation control while improving hemoglobin levels and reducing transfusion requirements, addressing a significant unmet need for patients with MF-related anemia.

In February 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired MorphoSys AG for EUR 2.7 billion ($2.91 billion). Through this acquisition, Novartis aims to obtain full ownership of pelabresib (CPI-0610), a promising therapy used in combination with ruxolitinib for myelofibrosis patients, as well as tulmimetostat (CPI-0209), an investigational dual EZH1/EZH2 inhibitor being evaluated for solid tumors and lymphomas. This strategic move strengthens Novartis’ oncology pipeline by adding innovative therapies that address critical unmet medical needs. MorphoSys AG is a Germany-based company specializing in the development of novel cancer treatments, including pelabresib for patients with myelofibrosis.

Major companies operating in the myelofibrosis (mf) market are Pfizer Inc, Novartis AG, Incyte Corporation, CTI BioPharma Corp, Karyopharm Therapeutics Inc, Sierra Oncology Inc, Kartos Therapeutics Inc, NS Pharma Inc, Keros Therapeutics Inc, Pharmaxis Ltd, Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, AbbVie Inc, Bristol‑Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Taiga Biotechnologies Inc, Rigel Pharmaceuticals Inc, Imago BioSciences Inc, Samus Therapeutics Inc.

North America was the largest region in the myelofibrosis (MF) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myelofibrosis (mf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myelofibrosis (mf) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on pharmaceutical raw materials and biologic ingredients have raised production and distribution costs in the myelofibrosis (mf) market, particularly affecting regions dependent on imported active ingredients. These disruptions impact drug availability in hospital and retail pharmacy channels and slow approval of new therapeutic options in cost-sensitive regions. However, tariffs have encouraged local manufacturing expansion and innovation, supporting long-term supply chain resilience.

The myelofibrosis (mf) market research report is one of a series of new reports that provides myelofibrosis (mf) market statistics, including myelofibrosis (mf) industry global market size, regional shares, competitors with a myelofibrosis (mf) market share, detailed myelofibrosis (mf) market segments, market trends and opportunities, and any further data you may need to thrive in the myelofibrosis (mf) industry. This myelofibrosis (mf) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Myelofibrosis (MF) is a rare bone marrow disorder characterized by the excessive formation of scar tissue, which interferes with normal blood cell production. This condition can result in anemia, enlargement of the spleen, and symptoms such as fatigue, night sweats, and bone pain.

The main drug types used in myelofibrosis include JAK inhibitors, immunomodulators, hydroxyurea, and other therapies. JAK inhibitors are medications that block Janus kinase enzymes, which are involved in signaling pathways regulating inflammation, immune responses, and cell growth, and are commonly used in conditions such as rheumatoid arthritis and myelofibrosis. Treatment options for MF include chemotherapy, targeted therapies, and other approaches. Routes of administration include oral, parenteral, and additional methods. These treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies and are used by end users such as hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The myelofibrosis (MF) market consists of revenues earned by entities by providing services such as diagnostic services, patient support programs, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The myelofibrosis (MF) market also includes sales of hematological diagnostic tools, novel fibrosis-targeting drugs, and evolving regenerative therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.